An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.

After trimming its cell therapy pipeline last year, the group is now out entirely.

Conference activity picks up, with the big one – ASCO – at the end of the month.

The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.

The Japanese group licenses sapablursen from Ionis for $280m.

Rusfertide, the subject of a 2024 tie-up, scores in phase 3.

Rusfertide’s big readout will now not come until 2025.